Mount Sinai Selected to Serve as Capacity Building Center and Center of Excellence as Part of the National Cancer Institute’s New Serological Sciences Network

Researchers from the Icahn School of Medicine at Mount Sinai will receive more than $7.3 million from the National Cancer Institute (NCI) as part of the NCI’s new Serological Sciences Network (SeroNet), one of the largest coordinated national efforts to study immunology and SARS-CoV-2, the virus that causes COVID-19. Mount Sinai was selected as one of only four Capacity Building Centers and one of eight Centers of Excellence as part of this new network.

Read more

Coronavirus antibodies fall dramatically in first 3 months after mild cases of COVID-19

A study by UCLA researchers shows that in people with mild cases of COVID-19, antibodies against SARS-CoV-2 — the virus that causes the disease — drop sharply over the first three months after infection, decreasing by roughly half every 73 days. If sustained at that rate, the antibodies would disappear within about a year.

Read more

COVID-19: What You Need to Know About Antibody Testing

As the number of COVID-19 cases in the U.S. surpasses 800,000, many Americans want to know if recovered patients have immunity to the novel coronavirus. The answer could come from an antibody test. While these tests are commonly used to tell if someone is immune to diseases such as measles or chickenpox, they’re not yet widely available for COVID-19. But it’s not clear what the results would mean.

Read more

Penn Medicine Launches COVID-19 Convalescent Plasma Study

Convalescent plasma therapy for COVID-19 patients — an experimental approach of giving a transfusion of plasma collected from a donor who has recovered from COVID-19 to a patient with an active infection — is the focus of a new two-part research initiative at Penn Medicine. Researchers will first collect plasma from people who have recovered from their infection under a donor research protocol. The second part involves conducting clinical trials to test the safety and efficacy of giving that plasma to moderately and severely ill hospitalized patients.

Read more